Author:
Onyango Hellen A.,Sloan Derek J,Keenan Katherine,Kesby Mike,Ngugi Caroline,Gitonga Humphrey,Hammond Robert
Abstract
AbstractBackgroundIn low- and- middle income countries, symptomatic urinary tract infection (UTI) patients are often prescribed antibiotics without microbiological confirmation. UTIs caused by antibiotic resistant bacteria are increasingly common and this heightens the risk of empirical treatment failure. This study evaluates the appropriateness of empirical antibiotic therapy to symptomatic UTI patients.MethodsA hospital-based, cross-sectional study was conducted in Nairobi County, Kenya among symptomatic adult and child patients. UTI was defined as a monoculture growth with colony counts of ≥104. cfu/ml. Antimicrobial susceptibility testing (AST) was performed by the Kirby-Bauer disc diffusion method. Empirical therapy was considered appropriate if the pathogen isolated was susceptible to the prescribed antibiotic and inappropriate if pathogen was resistant to prescribed antibiotic.ResultsA total of 552 participants were enrolled with a median age of 29 years (IQR:24-36). The majority were female; 398 (72%). Of the 552, 274 (50%) received empirical antibiotic therapy, 95/274 (35%) were confirmed to have UTI by culture. The antibiotics most frequently prescribed were fluoroquinolones [ciprofloxacin in 80 (30%) and levofloxacin 43 (16%)], amoxicillin-clavulanic-acid in 48 (18%), and nitrofurantoin in 32 (12%). Amongst the 95 patients with bacteriological confirmation of UTI, 50 (53%) received appropriate empirical antibiotic therapy, whilst for 38 (40%) participants, the therapy was inappropriate. Appropriateness of empirical therapy to 7 (7%) patients could not be determined as the antibiotics prescribed were not in the AST panel.ConclusionThe complexity of appropriate empirical treatment for UTIs is compounded by high levels of resistance in UTI pathogens. AMR surveillance strategies that could help in designing appropriate empirical regimens in resource constrained settings should be adopted for optimal empiric therapy.
Publisher
Cold Spring Harbor Laboratory
Reference38 articles.
1. Genetics of Antimicrobial Resistance
2. World Health Organization. Global Antimicrobial Resistance and Use Surveillance System 2022. https://www.who.int/publications/i/item/9789240062702
3. Neill JO ’. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance, 2014.
4. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
5. Laboratory Medicine in Africa: A Barrier to Effective Health Care